On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study

References

• Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62(2):195–201.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
   PubMed Web of Science ®Google Scholar
• Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017;13:315–323.
   PubMed Web of Science ®Google Scholar
• Ten Bergen LL, Petrovic A, Krogh Aarebrot A, et al. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020;31(5):476–483.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, et al. Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.
   PubMed Web of Science ®Google Scholar
• Bilal J, Berlinberg A, Bhattacharjee S, et al. A systematic review and Meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–578.
   PubMed Web of Science ®Google Scholar
• Facheris P, Valenti M, Pavia G, et al. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020;33(3):e13403.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC. Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis. Case Rep Dermatol. 2019;11(Suppl 1):1–3.
   PubMedGoogle Scholar
• Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5–21.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018;32(1):e32–e34.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Lam K, Sandhu VK, et al. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. J Eur Acad Dermatol Venereol. 2020;34(8):e416–e418.
   PubMed Web of Science ®Google Scholar
• Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017;53(5):283–297.
   PubMed Web of Science ®Google Scholar
• Ratner M. IL-17-targeting biologics aim to become standard of care in psoriasis. Nat Biotechnol. 2015;33(1):3–4.
   PubMed Web of Science ®Google Scholar
• Tong Y, Peranteau AJ, Nawas Z, et al. A review of brodalumab, an IL-17 receptor antagonist, for moderate-to-Severe plaque psoriasis. Skin Therapy Lett. 2017;22(1):1–6.
   PubMedGoogle Scholar
• van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112–118.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. J Drugs Dermatol. 2015;14(3):244–253.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Long-Term Benefit-Risk profiles of treatments for moderate-to-Severe plaque psoriasis: a network Meta-Analysis. Dermatol Ther (Heidelb). 2022;12(1):167–184.
   PubMed Web of Science ®Google Scholar
• Perrone V, Losi S, Maiorino A, et al. Treatment patterns and pharmacoutilization in patients affected by psoriasis: an observational study in an Italian Real-World setting. Drugs Real World Outcomes. 2022;9(2):243–251.
   PubMedGoogle Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36.e1.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–411.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017;31(6):1004–1013.
   PubMed Web of Science ®Google Scholar
• Michielsens CAJ, van Muijen ME, Verhoef LM, et al. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021;81(3):349–366.
   PubMed Web of Science ®Google Scholar
• Al-Hammadi A, Ruszczak Z, Magariños G, et al. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021;35(2):360–367.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63(5):769–774.
   PubMed Web of Science ®Google Scholar
• Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017;30(6).
   PubMed Web of Science ®Google Scholar
• Zhu SM, Wang WH, Guo JZ, et al. Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study. Chin Med J (Engl). 2020;133(24):3017–3019.
   PubMed Web of Science ®Google Scholar
• Colombo D, Bianchi L, Fabbrocini G, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022;35(1):e15166.
   PubMed Web of Science ®Google Scholar
• Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network Meta-Analysis. J Invest Dermatol. 2017;137(8):1646–1654.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138–1149.
   PubMed Web of Science ®Google Scholar
• Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-Severe plaque psoriasis: a comprehensive investigation using Bayesian and frequentist network Meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73–86.
   PubMed Web of Science ®Google Scholar
• Tada Y, Watanabe R, Noma H, et al. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network Meta-analysis. J Dermatol Sci. 2020;99(1):53–61.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network Meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535.
   PubMedGoogle Scholar
• Zagni E, Bianchi L, Fabbrocini G, et al. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res. 2021;21(1):924.
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther. 2020;33(3):e13313.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058.
   PubMed Web of Science ®Google Scholar
• Augustin M, Gallo G, See K, et al. Early response is associated with stable Long-Term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022;21(2):122–126.
   PubMed Web of Science ®Google Scholar
• Schweikert B, Malmberg C, Núñez M, et al. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open. 2020;10(8):e032552.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl). 2021;134(11):1324–1328.
   PubMed Web of Science ®Google Scholar
• Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(3):3156–3172.
   PubMed Web of Science ®Google Scholar
• Xu C, Teeple A, Wu B, et al. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. J Dermatolog Treat. 2022;1–8.
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304–315.
   PubMed Web of Science ®Google Scholar
• Reich K, Körber A, Mrowietz U, et al. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2021;184(5):849–856.
   PubMed Web of Science ®Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76.
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942–954.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Rovaris M, Piaserico S, et al. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2019;182(1):175–179.
   PubMed Web of Science ®Google Scholar
• Aichelburg MC, Tanew A. Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis – a simplified dosing regimen at the expense of efficacy? Br J Dermatol. 2020;182(1):18–19.
   PubMed Web of Science ®Google Scholar
• Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka university psoriasis registry. J Dermatol. 2019;46(5):389–398.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Warren RB, et al. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017;177(3):879–881.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Torisu-Itakura H, Morisaki Y, et al. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. J Eur Acad Dermatol Venereol. 2019;33(3):568–576.
   PubMed Web of Science ®Google Scholar
• Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311(5):421–424.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Phung M, Ighani A, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155–157.
   PubMed Web of Science ®Google Scholar
• Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2019;30(3):216–220.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021;21(2):279–286.
   PubMed Web of Science ®Google Scholar
• Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study. J Dermatolog Treat. 2021;32(8):878–882.
   PubMed Web of Science ®Google Scholar
• Menter A, Armstrong A, Van Voorhees A, et al. Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics. Dermatol Ther (Heidelb). 2020;10(4):615–621.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Fujita H, Ohtsuki M, Morita A, et al. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan. J Dermatol. 2021;48(2):175–183.
   PubMed Web of Science ®Google Scholar
• Huang H, Cai ML, Hong XJ, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020;30(5):554–560.
   PubMed Web of Science ®Google Scholar
• Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174–1185.
   PubMed Web of Science ®Google Scholar
• Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855–861.
   PubMed Web of Science ®Google Scholar
• Chen YC, Huang YT, Yang CC, et al. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: an analysis of 75 patients in Taiwan. PLoS One. 2020;15(12):e0244620.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatolog Treat. 2022;33(1):354–360.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yan K, Diao Q, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87(1):95–102.
   PubMedGoogle Scholar
• Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatolog Treat. 2015;26(2):103–112.
   PubMed Web of Science ®Google Scholar
• Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–79.
   PubMed Web of Science ®Google Scholar
• Veronesi G, Guglielmo A, Gardini A, et al. Biological therapy in patients with psoriasis: What we know about the effects on renal function. Dermatol Ther. 2022;35(1):e15202.
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062.
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–728.
   PubMed Web of Science ®Google Scholar
• Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter Real-Life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022;15(1):95.
   PubMedGoogle Scholar